Shingrix Purple Book BLA 125614

BLA number
125614
Proprietary names
Shingrix
Proper names
Zoster Vaccine Recombinant, Adjuvanted
Applicant
GlaxoSmithKline Biologicals
Center
CBER
First observed release
2020-08-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001ShingrixZoster Vaccine Recombinant, Adjuvanted351(a)0.5MLInjectionIntramuscularSingle-Dose VialRxLicensed2017-10-20
002ShingrixZoster Vaccine Recombinant, Adjuvanted351(a)50UGFor InjectionIntramuscularVialRxLicensed2021-07-23
003ShingrixZoster Vaccine Recombinant, Adjuvanted351(a)50UGInjectionIntramuscularPre-Filled SyringeRxLicensed2025-07-16

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2025-08-01U003Shingrix351(a)RxGlaxoSmithKline Biologicals
2021-07-01N002Shingrix351(a)RxGlaxoSmithKline Biologicals
2021-05-01U001Shingrix351(a)RxGlaxoSmithKline Biologicals
2020-08-01R001Shingrix351(a)RxGlaxoSmithKline Biologicals

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2025-08-01003Shingrix351(a)RxLicensed2025-07-16
2021-07-01002Shingrix351(a)RxLicensed2021-07-23
2020-08-01001Shingrix351(a)RxLicensed2017-10-20